In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …

Simple Summary Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy has emerged
as a new life-saving treatment modality in patients with relapsed or refractory B-cell …

With the introduction of anti‐CD19 chimeric antigen receptor (CAR) T‐cell (CAR T)
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …

ABSTRACT Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …

Simple Summary Despite the impressive efficacy of chimeric antigen receptor-T (CAR-T) cell
therapy in the treatment of some subtypes of lymphomas, many patients are either not …

CAR-T cell therapy is known as an effective therapy in patients with hematological
malignancies. Since 2017, several autologous CAR-T cell (auto-CAR-T) drugs have been …

Simple Summary Despite the impressive efficacy of chimeric antigen receptor-T (CAR-T) cell
therapy in the treatment of some subtypes of lymphomas, many patients are either not …

For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT)
has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …

Background Chimeric antigen receptor (CAR) T cells targeted to the CD19 B‐cell antigen
form an approved treatment for patients with relapsed/refractory diffuse large B‐cell …

While more than half of non-Hodgkin lymphomas (NHL) can be cured with modern frontline
chemoimmunotherapy regimens, outcomes of relapsed and/or refractory (r/r) disease in …